These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36642232)

  • 1. Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial.
    Veringa A; Brüggemann RJ; Span LFR; Biemond BJ; de Boer MGJ; van den Heuvel ER; Klein SK; Kraemer D; Minnema MC; Prakken NHJ; Rijnders BJA; Swen JJ; Verweij PE; Wondergem MJ; Ypma PF; Blijlevens N; Kosterink JGW; van der Werf TS; Alffenaar JC;
    Int J Antimicrob Agents; 2023 Feb; 61(2):106711. PubMed ID: 36642232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial.
    Park WB; Kim NH; Kim KH; Lee SH; Nam WS; Yoon SH; Song KH; Choe PG; Kim NJ; Jang IJ; Oh MD; Yu KS
    Clin Infect Dis; 2012 Oct; 55(8):1080-7. PubMed ID: 22761409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comment on 'Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: A multicentre, prospective, cluster randomised, crossover clinical trial'.
    Gautier-Veyret E; Thiebaut-Bertrand A; Stanke-Labesque F
    Int J Antimicrob Agents; 2023 Aug; 62(2):106853. PubMed ID: 37209956
    [No Abstract]   [Full Text] [Related]  

  • 4. In reply to comment on 'Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicenter, prospective, cluster randomised, crossover clinical trial'.
    Veringa A; Brüggemann RJ; Alffenaar JC;
    Int J Antimicrob Agents; 2023 Aug; 62(2):106854. PubMed ID: 37209957
    [No Abstract]   [Full Text] [Related]  

  • 5. Voriconazole therapeutic drug monitoring among lung transplant recipients receiving targeted therapy for invasive aspergillosis.
    Butler-Laporte G; Langevin MC; Lemieux C; Poirier C; Ferraro P; Théorêt Y; Luong ML
    Clin Transplant; 2022 Aug; 36(8):e14709. PubMed ID: 35575963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.
    Racil Z; Winterova J; Kouba M; Zak P; Malaskova L; Buresova L; Toskova M; Lengerova M; Kocmanova I; Weinbergerova B; Timilsina S; Rolencova M; Cetkovsky P; Mayer J
    Mycoses; 2012 Nov; 55(6):483-92. PubMed ID: 22429709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β-cyclodextrin in haematological patients with renal impairment.
    Kim SH; Kwon JC; Park C; Han S; Yim DS; Choi JK; Cho SY; Lee HJ; Park SH; Choi SM; Choi JH; Yoo JH; Lee DG; Lee JW
    Mycoses; 2016 Oct; 59(10):644-51. PubMed ID: 27324913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.
    Lee J; Ng P; Hamandi B; Husain S; Lefebvre MJ; Battistella M
    Ann Pharmacother; 2021 Apr; 55(4):509-529. PubMed ID: 32772568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Practice Guideline for the Therapeutic Drug Monitoring of Voriconazole in Non-Asian and Asian Adult Patients: Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.
    Takesue Y; Hanai Y; Oda K; Hamada Y; Ueda T; Mayumi T; Matsumoto K; Fujii S; Takahashi Y; Miyazaki Y; Kimura T;
    Clin Ther; 2022 Dec; 44(12):1604-1623. PubMed ID: 36424314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Voriconazole therapeutic drug monitoring: results of a prematurely discontinued randomized multicenter trial.
    Neofytos D; Ostrander D; Shoham S; Laverdiere M; Hiemenz J; Nguyen H; Clarke W; Brass L; Lu N; Marr KA
    Transpl Infect Dis; 2015 Dec; 17(6):831-7. PubMed ID: 26346408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Drug Monitoring of Voriconazole in Children with Hematologic Malignancy and Invasive Fungal Infections: An RCT from a Tertiary Care Centre in India.
    Sharad N; Singh G; Xess I; Agarwal R; Seth T; Reeta KH; Kothari S
    Cardiovasc Hematol Disord Drug Targets; 2023; 23(4):285-292. PubMed ID: 38192215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic drug monitoring and safety of voriconazole in elderly patients.
    Cheng L; Xiang R; Liu F; Li Y; Chen H; Yao P; Sun F; Xia P
    Int Immunopharmacol; 2020 Jan; 78():106078. PubMed ID: 31830620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The utility of voriconazole therapeutic drug monitoring in a multi-racial cohort in Southeast Asia.
    Zhou PY; Lim TP; Tang SLS; Liew Y; Chua SGN; Lim LLC; Lee HLW; Tan SX; Lai OF; Tan TT; Wong GC; Kwa LHA
    J Glob Antimicrob Resist; 2020 Jun; 21():427-433. PubMed ID: 31846723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial.
    Maertens JA; Rahav G; Lee DG; Ponce-de-León A; Ramírez Sánchez IC; Klimko N; Sonet A; Haider S; Diego Vélez J; Raad I; Koh LP; Karthaus M; Zhou J; Ben-Ami R; Motyl MR; Han S; Grandhi A; Waskin H;
    Lancet; 2021 Feb; 397(10273):499-509. PubMed ID: 33549194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Voriconazole therapeutic drug monitoring in critically ill patients improves efficacy and safety of antifungal therapy.
    Li H; Li M; Yan J; Gao L; Zhou L; Wang Y; Li Q; Wang J; Chen T; Wang T; Zheng J; Qiang W; Zhang Y; Shi Q
    Basic Clin Pharmacol Toxicol; 2020 Dec; 127(6):495-504. PubMed ID: 32639669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
    Howard A; Hoffman J; Sheth A
    Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Drug Monitoring of Voriconazole in Children from a Tertiary Care Center in China.
    Hu L; Dai TT; Zou L; Li TM; Ding XS; Yin T
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30150475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in the Treatment of Invasive Aspergillosis in Immunocompromised Children.
    Hsu AJ; Tamma PD; Fisher BT
    Antimicrob Agents Chemother; 2022 Jul; 66(7):e0215621. PubMed ID: 35766509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Optimized Voriconazole Dosing Strategy to Achieve Therapeutic Serum Concentrations in Children Younger than 2 Years Old.
    Zembles TN; Thompson NE; Havens PL; Kaufman BA; Huppler AR
    Pharmacotherapy; 2016 Oct; 36(10):1102-1108. PubMed ID: 27548272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voriconazole dosing and therapeutic drug monitoring in children: experience from a paediatric tertiary care centre.
    Boast A; Curtis N; Cranswick N; Gwee A
    J Antimicrob Chemother; 2016 Jul; 71(7):2031-6. PubMed ID: 27009030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.